earnings
confidence high
sentiment neutral
materiality 0.75
Regeneron Q3'25: Revenue $3.75B (+1%), GAAP EPS $13.62, Non-GAAP EPS $11.83; EYLEA sales down 28%
REGENERON PHARMACEUTICALS, INC.
2025-Q3 EPS reported
$33.61
revenue$10,458,600,000
- Total revenue $3.754B (+1% YoY); GAAP EPS $13.62 (+18%), non-GAAP EPS $11.83 (-5%).
- Dupixent global net sales (Sanofi) up 27% to $4.86B; total EYLEA HD+EYLEA U.S. down 28% to $1.11B.
- FDA approved Libtayo for adjuvant CSCC; positive Phase 3 data for cemdisiran in myasthenia gravis and DB-OTO gene therapy in hearing loss.
- 2025 guidance revised: GAAP R&D $5.68-5.75B, GAAP SG&A $2.775-2.845B, gross margin about 82%, ETR about 14%.